Article
A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
Cancer medicine - 1 Aug 2017
Izar Benjamin, Sharfman William, Hodi F Stephen, Lawrence Donald, Flaherty Keith T, Amaravadi Ravi, Kim Kevin B, Puzanov Igor, Sosman Jeffrey, Dummer Reinhard, Goldinger Simone M, Lam Lyhping, Kakar Shefali, Tang Zhongwen, Krieter Oliver, McDermott David F, Atkins Michael B
Abstract excerpt
To establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety profile, and anti-tumor efficacy of RAF265. We conducted a multicenter, open-label, phase-I, dose-escalation trial of RAF265, an orally available RAF kinase/VEGFR-2 inhibitor, in patients with advanced or metastatic melanoma. Pharmacokinetic (PK) analysis, pharmacodynamics (PD) and tumor response assessment were conducted. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.